Francesco Maria Venanzi
Overview
Explore the profile of Francesco Maria Venanzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
13
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogliari F, Traverso A, Barbieri S, Montagna M, Chiabrando F, Versino E, et al.
Lung Cancer
. 2025 Jan;
199:108075.
PMID: 39752796
Background: Artificial intelligence (AI) models are emerging as promising tools to identify predictive features among data coming from health records. Their application in clinical routine is still challenging, due to...
2.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi F, Riva S, et al.
Eur J Cancer
. 2023 Nov;
195:113404.
PMID: 37948842
Background: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing...
3.
Venanzi F, Bini M, Nuccio A, De Toma A, Lambertini M, Ogliari F, et al.
Cancer Treat Rev
. 2023 Nov;
121:102648.
PMID: 37918169
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immunecheckpoint blockade (ICI) in patients with cancer....
4.
Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, et al.
Oncologist
. 2023 Oct;
29(3):e372-e381.
PMID: 37796838
Background: Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors...